Presently, six active clinical trials involving trastuzumab deruxtecan are underway for NSCLC patients, including NCT05048797, a phase 3 study designed to assess both the efficacy and safety of trastuzumab deruxtecan in NSCLC patients with HER2 exon 19 or 20 mutant. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.